Bortezomib, a proteasome inhibitor, is capable to provoke neutropenia (65); reduction in T cell growth (58, 66); decrease of NK and CD8+ T cells (59); alteration of NK and CD8+T cells function (59); suppression of dendritic cells (67, 68) and changes in cytokine production (69). The gene discussed is CD8A; the disease is neutropenia.